JPH09176074A - Antimicrobial, antifungal and anti-inflammatory active substance and production thereof - Google Patents

Antimicrobial, antifungal and anti-inflammatory active substance and production thereof

Info

Publication number
JPH09176074A
JPH09176074A JP34291495A JP34291495A JPH09176074A JP H09176074 A JPH09176074 A JP H09176074A JP 34291495 A JP34291495 A JP 34291495A JP 34291495 A JP34291495 A JP 34291495A JP H09176074 A JPH09176074 A JP H09176074A
Authority
JP
Japan
Prior art keywords
peroxidase
isoeugenol
eugenol
compound
antifungal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP34291495A
Other languages
Japanese (ja)
Inventor
Akio Kobayashi
昭雄 小林
Takeshi Baba
健史 馬場
Shinichiro Kajiyama
慎一郎 梶山
Hiroshi Kanzaki
浩 神崎
Kazuyoshi Kawazu
一儀 河津
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kibun Foods Inc
Original Assignee
Kibun Foods Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kibun Foods Inc filed Critical Kibun Foods Inc
Priority to JP34291495A priority Critical patent/JPH09176074A/en
Publication of JPH09176074A publication Critical patent/JPH09176074A/en
Pending legal-status Critical Current

Links

Landscapes

  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

PROBLEM TO BE SOLVED: To obtain the above dimer exhibiting antimicrobial and antifungal, anti-inflammatory and anioxidizing activity and utilizable also as a pigment or dye by carrying out dimerization using peroxidase in the presence of hydrogen peroxide. SOLUTION: (A) Eugenol, isoeugenol or a mixture of eugenol with isoeugenol is dimerized (C) peroxidase to provide the objective dimer except a compound of formula I, preferably a dimer of formula II, etc. Moreover, the reaction is preferably carried out, e.g. in 1×10<-5> to 1×10<-4> mol/mg concentration of the component B in sodium phosphate buffer solution at about 25 deg.C.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【発明の属する技術分野】本明細書にて開示する発明
は、抗菌・抗カビまたは抗炎症活性物質、その製造方
法、および抗菌・抗カビまたは抗炎症剤に関する。
TECHNICAL FIELD The present invention disclosed herein relates to an antibacterial / antifungal or anti-inflammatory active substance, a method for producing the same, and an antibacterial / antifungal or anti-inflammatory agent.

【0002】[0002]

【従来の技術】植物は微生物の侵入に対してさまざまな
誘導抵抗反応を示すことが知られている。これは、遺伝
子的に制御されたさまざまな酵素の働きによるものであ
る。ペルオキシダーゼは、そのような誘導抵抗反応の発
現を活性化する酵素の1つであり、フェノール性化合物
を修飾・重合する作用を有することが知られている。し
かしながら、ペルオキシダーゼの働きによって生成する
化合物がいかなる構造を有する化合物であって、それが
どの程度の化学的・生理学的作用を示すのかという点に
ついては、いまだ十分に解明されていない。
2. Description of the Related Art It is known that plants show various induced resistance reactions to invasion of microorganisms. This is due to the action of various genetically regulated enzymes. Peroxidase is one of the enzymes that activates the expression of such induced resistance reaction, and is known to have an action of modifying and polymerizing a phenolic compound. However, the structure of the compound produced by the action of peroxidase and the degree of chemical / physiological action of the compound have not yet been sufficiently clarified.

【0003】[0003]

【発明が解決しようとする課題】そこで、本発明者ら
は、木本科植物に多く含まれるオイゲノールとイソオイ
ゲノールにペルオキシダーゼを作用させて得られる化合
物の分析を行うことによって、従来にない新規な抗菌・
抗カビおよび抗炎症活性物質を提供することを目的とし
て検討を進め、本明細書に開示する発明をなすに至っ
た。
Therefore, the present inventors have analyzed a compound obtained by allowing peroxidase to act on eugenol and isoeugenol, which are abundant in woody plants, to analyze a novel antibacterial agent that has not been found in the past.・
The inventors have proceeded with the study for the purpose of providing antifungal and antiinflammatory active substances, and have made the invention disclosed in the present specification.

【0004】[0004]

【課題を解決するための手段】本明細書において、オイ
ゲノール、イソオイゲノールまたはこれらの混合物を、
過酸化水素の存在下でペルオキシダーゼと反応させる発
明を開示する。
In the present specification, eugenol, isoeugenol or a mixture thereof is used.
The invention of reacting with peroxidase in the presence of hydrogen peroxide is disclosed.

【0005】この反応において出発物質として用いるオ
イゲノールとイソオイゲノールは、市販のものでも合成
されたものでもよい。イソオイゲノールはアリール基を
有するために幾何異性体が存在するが、シス体、トラン
ス体、両者の混合物のいずれを用いてもよい。また、ペ
ルオキシダーゼとの反応に悪影響を及ぼさないものであ
れば、反応時に他の物質が共存していてもよい。
Eugenol and isoeugenol used as starting materials in this reaction may be commercially available or synthesized. Since isoeugenol has an aryl group and therefore has a geometric isomer, any of a cis isomer, a trans isomer, and a mixture of both may be used. Further, other substances may coexist during the reaction as long as they do not adversely affect the reaction with peroxidase.

【0006】この反応で用いるペルオキシダーゼの種類
はとくに制限されない。したがって、西洋わさびやイン
ゲンなどから調製された粗酵素や商業的に入手できるも
のを用いることができる。
The type of peroxidase used in this reaction is not particularly limited. Therefore, a crude enzyme prepared from horseradish, green beans, or the like or a commercially available enzyme can be used.

【0007】オイゲノール等とペルオキシダーゼとの反
応は、過酸化水素の存在下で行う。過酸化水素の濃度
は、通常1mgあたり1x10-5mol〜1x10-4
olとするが、この範囲外の濃度であっても反応は実施
しうる。また、反応は緩衝液中で行ってもよい。緩衝液
としては、例えばリン酸ナトリウム緩衝液を用いること
ができる。反応温度は、ペルオキシダーゼが活性を示す
温度とすることができるが、通常は25℃前後で行う。
反応時間を長くしたり、濃度を高めたりすることによっ
て、活性が高い物質を製造することができる。なお、反
応の進行は適当な展開液を用いてTLCにより追跡する
ことができる。
The reaction between eugenol and the like and peroxidase is carried out in the presence of hydrogen peroxide. The concentration of hydrogen peroxide is usually 1 × 10 −5 mol to 1 × 10 −4 m per 1 mg.
However, the reaction can be carried out at a concentration outside this range. In addition, the reaction may be performed in a buffer solution. As the buffer solution, for example, a sodium phosphate buffer solution can be used. The reaction temperature may be a temperature at which peroxidase is active, but it is usually about 25 ° C.
By increasing the reaction time or increasing the concentration, a substance with high activity can be produced. The progress of the reaction can be followed by TLC using an appropriate developing solution.

【0008】反応生成物は、粗生成物のままでも抗菌・
抗カビ、抗炎症または抗酸化活性を示すことから、さら
に精製することなく粗生成物のままこれらの用途に用い
ることができる。しかし、粗生成物の中には活性が特に
強い化合物とそうでない化合物が混在している場合があ
るため、特に活性の強い化合物を精製して使用するのが
好ましい。精製は、カラムクロマトグラフィー、逆相カ
ラムクロマトグラフィー、分取HPLCなどの当業者に
周知の方法によって行うことができる。
The reaction product is antibacterial even if it is a crude product.
Since it exhibits antifungal, anti-inflammatory or antioxidant activity, it can be used in these applications as a crude product without further purification. However, in the crude product, there are cases where a compound having a particularly strong activity and a compound which does not have a particularly strong activity are mixed, and therefore it is preferable to purify and use the compound having a particularly strong activity. Purification can be performed by methods well known to those skilled in the art, such as column chromatography, reverse phase column chromatography, preparative HPLC and the like.

【0009】オイゲノール、イソオイゲノールまたはこ
れらの混合物をペルオキシダーゼと反応させることによ
って、二量体を中心とする重合体混合物が得られる。反
応物質として通常のフェノール性化合物を用いた場合
は、ペルオキシダーゼとの反応によってさまざまな重合
度の化合物の混合物が得られるのが普通である。例え
ば、グアイアコールとペルオキシダーゼとの反応では、
二量体から少なくとも十量体までのさまざまな重合体の
混合物が得られることが確認されている(実施例参
照)。このように、本明細書に開示する方法によれば、
活性が高い二量体を主とする反応生成物を容易に得るこ
とができるという利点がある。
By reacting eugenol, isoeugenol or a mixture thereof with peroxidase, a dimer-centered polymer mixture is obtained. When a conventional phenolic compound is used as a reactant, a reaction with peroxidase usually gives a mixture of compounds having various degrees of polymerization. For example, in the reaction between guaiacol and peroxidase,
It has been determined that mixtures of various polymers from dimers to at least decamers are obtained (see Examples). Thus, according to the methods disclosed herein,
There is an advantage that a reaction product mainly containing a dimer having high activity can be easily obtained.

【0010】オイゲノール、イソオイゲノールまたはこ
れらの混合物をペルオキシダーゼと反応させることによ
って、以下の式で表される化合物が生成することが確認
されている。
It has been confirmed that by reacting eugenol, isoeugenol or a mixture thereof with peroxidase, a compound represented by the following formula is produced.

【0011】[0011]

【化5】 これらの化合物は、いずれも抗菌・抗カビ、抗炎症、抗
酸化活性を示すものである。また、これらの化合物の中
には良好な色を有しているものもあり、色素や染料とし
ての用途も期待しうる。
Embedded image All of these compounds exhibit antibacterial / antifungal, anti-inflammatory and antioxidant activities. Further, some of these compounds have a good color, and can be expected to be used as pigments and dyes.

【0012】[0012]

【実施例】以下に実施例を挙げて、本発明を具体的に説
明するが、本発明の技術的範囲はこれらの実施例によっ
て何ら制限的に解釈されるものではない。
EXAMPLES The present invention will be specifically described below with reference to examples, but the technical scope of the present invention is not limited to these examples.

【0013】(実施例1)オイゲノール1.6g、0.
35%過酸化水素水32ml、西洋ワサビより調製した
ペルオキシダーゼ(ナカライ製、PEO−131:I−
C級)40,000ユニット(東洋紡の定義による)お
よび0.1Mリン酸ナトリウム緩衝液の混合物を、25
℃で30分間インキュベーションした。混合物を取り出
し、メタノールを添加して酵素を不活性化した後、以下
の4種の菌に対する最小阻害濃度(MIC)を調べて抗
菌・抗カビ活性の変化を検討した。
Example 1 Eugenol 1.6 g, 0.
32 ml of 35% hydrogen peroxide water, peroxidase prepared from horseradish (Nakarai, PEO-131: I-
C) 40,000 units (as defined by Toyobo) and 0.1M sodium phosphate buffer at 25
Incubated at 30 ° C for 30 minutes. After the mixture was taken out and methanol was added to inactivate the enzyme, the minimum inhibitory concentration (MIC) against the following four kinds of bacteria was examined to examine changes in antibacterial / antifungal activity.

【0014】バシラス サブチリス(Bacillus
subtilis)およびエッシェリヒア コリー(
scherichia coli)を、NBSY培地1
0mlを用いて、直径25mmの試験官内で27℃24
時間往復振盪することによって培養した。得られた対数
後期あるいは定常期初期の培養液をNBSY培地で10
0倍希釈して抗菌試験に用いた。試料を96穴マイクロ
アッセイプレート(丸底)の第一穴に入れ、調製した菌
体懸濁液を分注し、第一穴から公比2で希釈した系列を
作った。これを27℃にて24時間暗黒下で培養し、微
生物の増殖を肉眼で観察した。透明であれば活性があ
り、微生物の増殖により白濁していれば活性なしとし
た。微生物の生育を阻止した最低濃度を最小阻害濃度
(MIC)とした。
[0014] Bacillus subtilis (Bacillus
subtilis ) and Escherichia coli ( E
scherichia coli ) in NBSY medium 1
Use 0 ml in a tester with a diameter of 25 mm at 27 ° C 24
Culture was performed by shaking back and forth for an hour. The obtained culture solution in the late logarithm or the early stationary phase was diluted with NBSY medium to 10
It was diluted 0-fold and used for the antibacterial test. The sample was put in the first hole of a 96-well microassay plate (round bottom), the prepared cell suspension was dispensed, and a series diluted with a common ratio of 2 from the first hole was prepared. This was cultured at 27 ° C. for 24 hours in the dark, and the growth of microorganisms was visually observed. If it was transparent, it was considered to be active. The minimum concentration that inhibited the growth of microorganisms was defined as the minimum inhibitory concentration (MIC).

【0015】アスペルギルス キャンディダス(Asp
ergillus candidus)およびクラドス
ポリウム ハーバラム(Cladosporium he
rbarum)に対しては、被検菌の胞子を胞子発芽用
培地(グルコース0.2%、イーストエキストラクト
0.1%、NaHPO4・12H2O 0.37%、クエ
ン酸0.1%)に懸濁し、それぞれ試料濃度を1000
μg/ml、500μg/ml、250μg/ml、1
25μg/ml、63μg/ml、として27℃で培養
し、24時間後に胞子の発芽が認められるか否かを顕微
鏡で観察することによって行った。
Aspergillus Candidas ( Asp
ergillus candidus ) and Cladosporium herbalum ( Cladosporium he
rbarum ), the spores of the test bacterium are spore germination medium (glucose 0.2%, yeast extract 0.1%, NaHPO 4 .12H 2 O 0.37%, citric acid 0.1%). Suspended in water and the sample concentration was adjusted to 1000
μg / ml, 500 μg / ml, 250 μg / ml, 1
The culture was carried out at 27 ° C. as 25 μg / ml and 63 μg / ml, and it was carried out by observing with a microscope whether spore germination was observed after 24 hours.

【0016】以上の操作を、オイゲノールの代わりにイ
ソオイゲノールを用いて繰り返した。抗菌・抗カビ活性
試験の結果は以下の表に示すとおりであった。
The above operation was repeated using isoeugenol instead of eugenol. The results of the antibacterial / antifungal activity test are shown in the table below.

【0017】[0017]

【表1】 [Table 1]

【0018】各反応生成物を、MALDI TOF MS
スペクトル分析したところ、326にピークが観測さ
れ、主として二量体が生成していることが判明した。一
方、比較のためにオイゲノール等の代わりにグアイアコ
ールを用いて上記方法を繰返し、反応生成物を得てMA
LDI TOF MSスペクトル分析をしたところ、36
8,490,612,734,855,978,109
8,1286にピークが観測された。
Each reaction product was analyzed by MALDI TOF MS.
As a result of spectrum analysis, a peak was observed at 326, and it was found that a dimer was mainly produced. On the other hand, for comparison, the above method was repeated using guaiacol instead of eugenol or the like to obtain a reaction product and to obtain MA.
LDI TOF MS spectrum analysis showed 36
8,490,612,734,855,978,109
A peak was observed at 8,1286.

【0019】オイゲノールの反応生成物400mgを、
カラムクロマトグラフィー(Wakogel C−10
0;f2.0x25cm)によって精製した。溶出液と
して、酢酸エチルの濃度を0〜70%まで10%ずつ上
げたヘキサン溶液を各200mlずつ用いた。20%酢
酸エチル200mlの画分から化合物1を得て、40%
酢酸エチル200mlの画分から化合物2を得た。
400 mg of the reaction product of eugenol,
Column chromatography (Wakogel C-10
0; f2.0 × 25 cm). As an eluent, 200 ml of each hexane solution in which the concentration of ethyl acetate was increased by 10% from 0 to 70% was used. Compound 1 was obtained from the fraction of 200 ml of 20% ethyl acetate, 40%
Compound 2 was obtained from a fraction of 200 ml of ethyl acetate.

【0020】イソオイゲノールの反応生成物1700m
gを、中圧カラム(WakogelC−200;f2.
0x60cm;20ml/min)を用いて精製した。
溶出液は、酢酸エチルの濃度を0〜70%まで上げたヘ
キサン溶液を用いた。50%酢酸エチルの画分から化合
物3を得た。
Isoeugenol reaction product 1700 m
g for medium pressure column (Wakogel C-200; f2.
0x60 cm; 20 ml / min).
As the eluent, a hexane solution in which the concentration of ethyl acetate was increased to 0 to 70% was used. Compound 3 was obtained from the 50% ethyl acetate fraction.

【0021】イソオイゲノールの反応生成物1700m
gを、中圧カラム(WakogelC−200;f2.
0x60cm;20ml/min)を用いて精製した。
溶出液は、酢酸エチルの濃度を0〜70%まで上げたヘ
キサン溶液を用いた。50%酢酸エチルの画分より精製
物を得た。これをさらに中圧カラム(Millipor
e Preparative C18125A;f1.
0x100cm;0.8ml/min)を用いて精製し
た。30%〜80%メタノール溶液を用いて溶出し、8
0%メタノール溶液の画分から化合物4を得た。
Isoeugenol reaction product 1700 m
g for medium pressure column (Wakogel C-200; f2.
0x60 cm; 20 ml / min).
As the eluent, a hexane solution in which the concentration of ethyl acetate was increased to 0 to 70% was used. A purified product was obtained from the 50% ethyl acetate fraction. This is a medium pressure column (Millipor
e Preparative C18125A; f1.
0x100 cm; 0.8 ml / min). Elute with 30% -80% methanol solution, 8
Compound 4 was obtained from the fraction of 0% methanol solution.

【0022】イソオイゲノールの反応生成物1600m
gを、オープンカラム(Wakogel C−100;
f3.3x37cm)を用いて精製した。溶出液は、酢
酸エチルの濃度を0〜50%まで5%ずつ上げたヘキサ
ン溶液を各400mlずつ用いた。得られた精製物を、
中圧カラム(YMG GEL ODS−AQ120−S5
0;f0.4x50cm;0.25ml/min)を用
いて精製した。溶出液として、60%メタノール溶液と
70%メタノール溶液を用い、70%メタノール溶液の
画分から精製物を得た。さらに、分取HPLC(NUC
LEOSIL5C18;f4.6x250mm)により
メタノール溶液を用いて精製することによって化合物5
を得た。
Reaction product of isoeugenol 1600 m
g is an open column (Wakogel C-100;
f3.3 x 37 cm). As the eluent, 400 ml of each hexane solution in which the concentration of ethyl acetate was increased by 5% from 0 to 50% was used. The obtained purified product is
Medium pressure column (YMG GEL ODS-AQ120-S5
0; f0.4 × 50 cm; 0.25 ml / min). A 60% methanol solution and a 70% methanol solution were used as eluents, and a purified product was obtained from a fraction of the 70% methanol solution. In addition, preparative HPLC (NUC
Compound 5 by purification with a solution in methanol according to LEOSIL 5C18; f4.6 x 250 mm)
I got

【0023】化合物1−5の同定データと構造式は以下
に示すとおりであった。
The identification data and structural formula of compound 1-5 are shown below.

【0024】[化合物1] NMR δH(500MHz,CDCl3):3.34
(2H,d,J=6.8Hz),3.89(3H,
s),5.04(1H,dd,J=8.8,1.6H
z),5.09(1H,dd,J=17.0,1.6H
z),5.96(1H,dd,J=17.0,8.8,
6.6Hz),5.98(1H,s),6.70(1
H,d,J=1.9Hz),6.73(1H,d,J=
1.9Hz); UV λmax(メタノール)nm:222,290 (+NaOH):211,231,312 二酢酸塩のEIMS m/z=410(M+,8),36
8(M+−Ac,48),326(M+・Acx2,10
0),284(8),253(3)
[Compound 1] NMR δ H (500 MHz, CDCl 3 ): 3.34
(2H, d, J = 6.8Hz), 3.89 (3H,
s), 5.04 (1H, dd, J = 8.8, 1.6H)
z), 5.09 (1H, dd, J = 17.0, 1.6H
z), 5.96 (1H, dd, J = 17.0, 8.8,
6.6 Hz), 5.98 (1 H, s), 6.70 (1
H, d, J = 1.9 Hz), 6.73 (1 H, d, J =
UV λ max (methanol) nm: 222,290 (+ NaOH): 211, 231, 312 EIMS of diacetate m / z = 410 (M + , 8), 36.
8 (M + -Ac, 48), 326 (M + -Acx2, 10)
0), 284 (8), 253 (3)

【化6】 [化合物2] NMR δH(500MHz,CDCl3):3.21
(2H,d,J=6.4Hz),3.34(2H,d,
J=6.7Hz),3.84(3H,s),3.87
(3H,s),4.99(1H,dd,J=9.8,
1.2Hz),5.00(1H,dd,J=9.8,
1,2Hz),5.81(1H,s),5.82−5.
98(2H,m),6.37(1H,d,J=1.4H
z),6.47(1H,d,J=1.4Hz),6.6
8(1H,dd,J=8.1,1.7Hz),6.77
(1H,d,J=1.7Hz),6.86(1H,d,
J=8.1Hz) UV λmax(メタノール)nm:217,273 (+NaOH):214,268 EIMS m/z=326(M+,99)
[Chemical 6] [Compound 2] NMR δ H (500 MHz, CDCl 3 ): 3.21
(2H, d, J = 6.4 Hz), 3.34 (2H, d,
J = 6.7 Hz), 3.84 (3H, s), 3.87.
(3H, s), 4.99 (1H, dd, J = 9.8,
1.2 Hz), 5.00 (1H, dd, J = 9.8,
1,2 Hz), 5.81 (1H, s), 5.82-5.
98 (2H, m), 6.37 (1H, d, J = 1.4H
z), 6.47 (1H, d, J = 1.4 Hz), 6.6
8 (1H, dd, J = 8.1, 1.7Hz), 6.77
(1H, d, J = 1.7 Hz), 6.86 (1H, d,
J = 8.1 Hz) UV λ max (methanol) nm: 217,273 (+ NaOH): 214,268 EIMS m / z = 326 (M + , 99)

【化7】 [化合物3] NMR δH(500MHz,CDCl3):1.38
(3H,d,J=6.7Hz),1.87(3H,d
d,J=6.6,1.6Hz),3.45(1H,d
q,J=9.5,6.7Hz),3.88(3H,
s),3.89(3H,s),5.10(1H,d,J
=9.5Hz),5.62(1H,s),6.10(1
H,dq,J=15.6,6.6Hz),6.36(1
H,dq,J=15.6,1.6Hz),6.76(1
H,s),6.78(1H,s),6.89−6.90
(2H,m),6.97(1H,d,J=1.5Hz) UV λmax(メタノール)nm:214,247,2
88 (+NaOH):211,257,315 EIMS m/z=326(M+,100),311(1
1),283(5),202(10),163(7),
137(9)
Embedded image [Compound 3] NMR δ H (500 MHz, CDCl 3 ): 1.38
(3H, d, J = 6.7 Hz), 1.87 (3H, d
d, J = 6.6, 1.6 Hz), 3.45 (1H, d
q, J = 9.5, 6.7 Hz), 3.88 (3H,
s), 3.89 (3H, s), 5.10 (1H, d, J
= 9.5 Hz), 5.62 (1 H, s), 6.10 (1
H, dq, J = 15.6, 6.6 Hz), 6.36 (1
H, dq, J = 15.6, 1.6 Hz), 6.76 (1
H, s), 6.78 (1H, s), 6.89-6.90.
(2H, m), 6.97 (1H, d, J = 1.5Hz) UV λ max (methanol) nm: 214, 247, 2
88 (+ NaOH): 211, 257, 315 EIMS m / z = 326 (M + , 100), 311 (1
1), 283 (5), 202 (10), 163 (7),
137 (9)

【化8】 [化合物4] NMR δH(500MHz,CDCl3):1.18
(3H,d,J=6.4Hz),1.94(3H,d
d,J=7.2,1.8Hz) ,3.45(1H,b
rs),3.89(3H,s),3.90(3H,
s),4.36(1H,dq,J=8.4,3.0H
z),4.83(1H,d,J=3.0Hz),5.5
5(1H,s),5.76(1H,dq,J=11.
5,7.2Hz),8.38(1H,dd,J=11.
5,1.8Hz),6.75(1H,dd,J=8.
2,1.8Hz),6.86(1H,d,J=8.2H
z),6.87(1H,d,J=2.2Hz),6.8
9(1H,dd,J=6.2,2.0Hz),6.99
(1H,s),7.00(1H,d,J=7.9Hz) アセチル化によってδ4.36はδ5.70にシフトし
たためラセミ体が生成していることが確認された。
Embedded image [Compound 4] NMR δ H (500 MHz, CDCl 3 ): 1.18
(3H, d, J = 6.4 Hz), 1.94 (3H, d
d, J = 7.2, 1.8 Hz), 3.45 (1H, b
rs), 3.89 (3H, s), 3.90 (3H,
s), 4.36 (1H, dq, J = 8.4, 3.0H
z), 4.83 (1H, d, J = 3.0 Hz), 5.5
5 (1H, s), 5.76 (1H, dq, J = 11.
5, 7.2 Hz), 8.38 (1H, dd, J = 11.
5,1.8 Hz), 6.75 (1H, dd, J = 8.
2,1.8Hz), 6.86 (1H, d, J = 8.2H)
z), 6.87 (1H, d, J = 2.2 Hz), 6.8
9 (1H, dd, J = 6.2, 2.0 Hz), 6.99
(1H, s), 7.00 (1H, d, J = 7.9 Hz) Due to acetylation, δ4.36 was shifted to δ5.70, so that it was confirmed that a racemate was produced.

【0025】EIMS m/z=344(M+,26),
326(2),259(5),191(24),164
(108),153(40)
EIMS m / z = 344 (M + , 26),
326 (2), 259 (5), 191 (24), 164
(108), 153 (40)

【化9】 [化合物5] NMR δH(500MHz,CDCl3):1.15
(3H,d,J=6.4Hz),1.88(3H,d
d,J=6.6,1.7Hz),3.89(3H,
s),3.92(3H,s),4.08(1H,dq,
J=6.2,6.4Hz),4.11(1H,s),
4.61(1H,s,J=8.2Hz),5.59(1
H,s),6.41(1H,dq,J=15.7,6.
6Hz),6.35(1H,dd,J=15.7,1.
7Hz),6.85(1H,dd,J=7.9,1.7
Hz),6.86(1H,d,J=1.7Hz),6.
87(1H,d,J=7.9Hz),6.91(1H,
dd,J=7.0,1.2Hz),6.92(1H,
s),6.93(1H,d,J=7.0Hz) アセチル化によってδ4.08はδ4.54にシフトし
たためラセミ体が生成していることが確認された。
Embedded image [Compound 5] NMR δ H (500 MHz, CDCl 3 ): 1.15
(3H, d, J = 6.4 Hz), 1.88 (3H, d
d, J = 6.6, 1.7 Hz), 3.89 (3H,
s), 3.92 (3H, s), 4.08 (1H, dq,
J = 6.2, 6.4 Hz), 4.11 (1H, s),
4.61 (1H, s, J = 8.2Hz), 5.59 (1
H, s), 6.41 (1H, dq, J = 15.7, 6.
6 Hz), 6.35 (1H, dd, J = 15.7, 1.
7 Hz), 6.85 (1H, dd, J = 7.9, 1.7)
Hz), 6.86 (1H, d, J = 1.7 Hz), 6.
87 (1H, d, J = 7.9 Hz), 6.91 (1H,
dd, J = 7.0, 1.2 Hz), 6.92 (1H,
s), 6.93 (1H, d, J = 7.0 Hz) Due to acetylation, δ4.08 was shifted to δ4.54, which confirmed that a racemic body was formed.

【0026】EIMS m/z=344(M+,6),3
26(18),283(5),251(5),164
(100),149(22)
EIMS m / z = 344 (M + , 6), 3
26 (18), 283 (5), 251 (5), 164
(100), 149 (22)

【化10】 化合物1−5の抗菌・抗カビ活性を上述の方法により試
験した。なお、うに卵細胞毒性試験に用いた卵と***
は、繁殖期(1−3月)に岡山で収集した性成熟ウニ
Hemicentrotus pulcherrim
us)から取り出した。卵は撹拌して3分間静置し、表
面と底にある卵をそれぞれ傾斜法と吸引法により除去し
たものを用いた。連続希釈試料溶液に約100個の受精
卵を添加し、胚の形態変化を観察することによって、植
物抽出物の細胞毒性を評価した。結果は以下の表に示す
とおりであった。
Embedded image Compound 1-5 was tested for antibacterial and antifungal activity by the method described above. The eggs and semen used in the sea urchin cytotoxicity test were sexually mature sea urchins ( Hemicentrotus pulcherrim ) collected in Okayama during the breeding season (January-March).
us )). The eggs were stirred and allowed to stand for 3 minutes, and the eggs on the surface and the bottom were removed by the tilting method and the suction method, respectively. The cytotoxicity of the plant extract was evaluated by adding about 100 fertilized eggs to the serially diluted sample solution and observing the morphological change of the embryo. The results were as shown in the table below.

【0027】[0027]

【表2】 [Table 2]

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 // C07C 37/14 9155−4H C07C 37/14 (72)発明者 河津 一儀 岡山県岡山市宿本町8−51−12─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI Technical display location // C07C 37/14 9155-4H C07C 37/14 (72) Inventor Kazuyoshi Kawazu Okayama City, Okayama Prefecture 8-51-12 Sukumotocho

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】オイゲノール、イソオイゲノールまたはオ
イゲノールとイソオイゲノールの混合物を、過酸化水素
の存在下でペルオキシダーゼを用いて二量化して得られ
る二量体(ただし、式: 【化1】 で表される化合物を除く)。
1. A dimer obtained by dimerizing eugenol, isoeugenol or a mixture of eugenol and isoeugenol with peroxidase in the presence of hydrogen peroxide (provided that the formula: Excluding compounds represented by).
【請求項2】以下のいずれかの式で表される二量体。 【化2】 2. A dimer represented by one of the following formulas. Embedded image 【請求項3】オイゲノールまたはイソオイゲノールを過
酸化水素の存在下でペルオキシダーゼと反応させること
によって二量化する工程を含む、以下のいずれかの式で
表される二量体の製造方法。 【化3】
3. A method for producing a dimer represented by any one of the following formulas, which comprises a step of dimerizing eugenol or isoeugenol with peroxidase in the presence of hydrogen peroxide. Embedded image
【請求項4】以下のいずれかの式で表される二量体を含
有する抗菌・抗カビまたは抗炎症剤。 【化4】
4. An antibacterial / antifungal or anti-inflammatory agent containing a dimer represented by any one of the following formulas. Embedded image
JP34291495A 1995-12-28 1995-12-28 Antimicrobial, antifungal and anti-inflammatory active substance and production thereof Pending JPH09176074A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP34291495A JPH09176074A (en) 1995-12-28 1995-12-28 Antimicrobial, antifungal and anti-inflammatory active substance and production thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP34291495A JPH09176074A (en) 1995-12-28 1995-12-28 Antimicrobial, antifungal and anti-inflammatory active substance and production thereof

Publications (1)

Publication Number Publication Date
JPH09176074A true JPH09176074A (en) 1997-07-08

Family

ID=18357504

Family Applications (1)

Application Number Title Priority Date Filing Date
JP34291495A Pending JPH09176074A (en) 1995-12-28 1995-12-28 Antimicrobial, antifungal and anti-inflammatory active substance and production thereof

Country Status (1)

Country Link
JP (1) JPH09176074A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006388A3 (en) * 1997-07-31 1999-04-22 Electrophoretics International Pharmaceutical compounds isolated from aristolochia taliscana
EP1865937A1 (en) * 2005-03-18 2007-12-19 Colgate-Palmolive Company Antibacterial 5',5-disubstituted 3,3'-dialkoxy-2,2'-dihydroxy- 1,1'-biphenyl compounds and related methods
US8071077B2 (en) 2004-12-29 2011-12-06 Colgate-Palmolive Company Oral compositions containing biphenol antibacterial compounds
JP2012528825A (en) * 2009-06-05 2012-11-15 ビーエーエスエフ ソシエタス・ヨーロピア Process for producing an asymmetric biaryl alcohol
US8425881B2 (en) 2005-03-18 2013-04-23 Colgate-Palmolive Company Antibacterial 3′,5-disubstituted 2,4′-dihydroxybiphenyl compounds, derivatives and related methods

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006388A3 (en) * 1997-07-31 1999-04-22 Electrophoretics International Pharmaceutical compounds isolated from aristolochia taliscana
US8071077B2 (en) 2004-12-29 2011-12-06 Colgate-Palmolive Company Oral compositions containing biphenol antibacterial compounds
US8652444B2 (en) 2004-12-29 2014-02-18 Colgate-Palmolive Company Oral compositions containing biphenol antibacterial compounds
EP1865937A1 (en) * 2005-03-18 2007-12-19 Colgate-Palmolive Company Antibacterial 5',5-disubstituted 3,3'-dialkoxy-2,2'-dihydroxy- 1,1'-biphenyl compounds and related methods
US8313733B2 (en) * 2005-03-18 2012-11-20 Colgate-Palmolive Company Antibacterial 5,5′-disubstituted 3,3′ dialkoxy-2,2′-dihydroxy-1,1′-biphenyl
US8425881B2 (en) 2005-03-18 2013-04-23 Colgate-Palmolive Company Antibacterial 3′,5-disubstituted 2,4′-dihydroxybiphenyl compounds, derivatives and related methods
JP2012528825A (en) * 2009-06-05 2012-11-15 ビーエーエスエフ ソシエタス・ヨーロピア Process for producing an asymmetric biaryl alcohol

Similar Documents

Publication Publication Date Title
Carmi et al. (+)-(S)-dihydroaeruginoic acid, an inhibitor of Septoria tritici and other phytopathogenic fungi and bacteria, produced by Pseudomonas fluorescens
JP2012528080A (en) New anthraquinone derivatives
JPH09176074A (en) Antimicrobial, antifungal and anti-inflammatory active substance and production thereof
US4376778A (en) Antibiotic substances and processes for production thereof
Salih et al. Synthesis, Characterization, and Anti-Microbial Study of Metal Complexes of Polycyclicacetal Derived from PVA & Erythro-Ascorbic Acid Derivative.
JPS6053597B2 (en) New antibiotic N-461 substance, its manufacturing method, and agricultural and horticultural fungicides containing it as an active ingredient
JPH09176075A (en) Antimicrobial, antifungal and anti-inflammatory active substance and production thereof
CN113024404B (en) Quaternary amine salt type honokiol/magnolol derivative and preparation method and application thereof
JP5878303B2 (en) Antibiotic-containing fraction, its antibiotic and method for producing the antibiotic
EP2519218B1 (en) Dibenzoyl peroxide derivatives, preparation method thereof and cosmetic or dermatological compositions containing same
JPH06116197A (en) New radical scavenger
JP2764759B2 (en) Novel substance BT-38 substance, method for producing the same and antifungal agent containing the same as an active ingredient
KR101598015B1 (en) Method for synthesizing derivatives of 6-O-cinnamoyl-sorbitol acid using enzyme
Bello et al. POTENT IN VITRO BIOLOGICAL ACTIVITY OF SOME DERIVATIVES OF SYNTHESIZED C-9154 ANTIBIOTIC
WO2004112479A1 (en) Derivatives comprising a phenylethanol backbone and preparation method thereof
JPS6351395A (en) Antibiotic sf-2415 and production thereof
JP4469279B2 (en) Polyisoprenylbenzophenone derivative, process for producing the same and use thereof
Younus et al. Synthesis, Characterization, and Anti-microbial Study of Polycyclicacetal Metal Complexes Derived from PEG and (Erythro-Ascorbic Acid) Derivative
JPH0196189A (en) Novel antibiotic sf2446a2 substance, sf2446a3 substance, sf2446 b1 substance, sf2446b2 substance and sf2446b3 substance
FR2585022A1 (en) NEW MACROLIDE ANTIBIOTIC M 119
JPH05310727A (en) Kojic acid dimer as physiologically active substance, its production and skin whitening agent with the same as active ingredient
FR2550536A1 (en) DESACETYL-RAVIDOMYCIN, METHOD FOR PRODUCING THE SAME, AND THERAPEUTIC USE THEREOF
JPH0522514B2 (en)
JPH10168009A (en) Binaphthalene derivative
JPS6257199B2 (en)

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20060308